BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34077005)

  • 1. Clinical efficacy analysis of Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with Paclitaxel-Cisplatin Chemotherapy in patients with Advanced Ovarian Cancer.
    Gao Y; Hao Y; Jia Y
    J BUON; 2021; 26(2):553-560. PubMed ID: 34077005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer.
    Tian L; Wang W; Yu B; Zhang G
    J BUON; 2020; 25(5):2364-2370. PubMed ID: 33277857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer.
    Liu G; Chen D; Zhao X; You X; Huang C; Cheng Z; Mao X; Zhou H
    J Oncol; 2022; 2022():5473292. PubMed ID: 35865086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
    Lin T; Song C; Chuo DY; Zhang H; Zhao J
    Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.
    Yuan X; Zhang AZ; Ren YL; Wang XL; Jiang CH; Yang L; Liu CX; Liang WH; Pang LJ; Gu WY; Li F; Hu JM
    Medicine (Baltimore); 2021 Apr; 100(13):e24519. PubMed ID: 33787569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
    Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
    Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
    Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
    Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis.
    Mu Y; Zhou CH; Chen SF; Ding J; Zhang YX; Yang YP; Wang WH
    Cytotherapy; 2016 Sep; 18(9):1162-77. PubMed ID: 27421742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
    Qiao G; Wang X; Zhou L; Zhou X; Song Y; Wang S; Zhao L; Morse MA; Hobeika A; Song J; Yi X; Xia X; Ren J; Lyerly HK
    Clin Cancer Res; 2019 Mar; 25(5):1494-1504. PubMed ID: 30514775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.
    Chen S; Yang Y; Jiao Y; Sun H; Yan Z
    J BUON; 2021; 26(3):734-740. PubMed ID: 34268928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
    Jiang N; Qiao G; Wang X; Morse MA; Gwin WR; Zhou L; Song Y; Zhao Y; Chen F; Zhou X; Huang L; Hobeika A; Yi X; Xia X; Guan Y; Song J; Ren J; Lyerly HK
    Clin Cancer Res; 2017 Sep; 23(17):5066-5073. PubMed ID: 28611200
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
    Xie Y; Huang L; Chen L; Lin X; Chen L; Zheng Q
    World J Surg Oncol; 2017 Nov; 15(1):209. PubMed ID: 29179719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis.
    Liu YL; Yang LX; Zhang F; Tang BS; Zhao LT; Zhu JR; Jin QY; Wang RX; Li YM
    Cytotherapy; 2019 Oct; 21(10):1064-1080. PubMed ID: 31462394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
    Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
    Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.
    Zhao X; Ji CY; Liu GQ; Ma DX; Ding HF; Xu M; Xing J
    Int J Clin Exp Pathol; 2015; 8(10):13146-55. PubMed ID: 26722513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
    Li DP; Li W; Feng J; Chen K; Tao M
    Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
    Wang S; Wang Z
    Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
    J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.